Department of Life Sciences, Central University of Tamil Nadu, Thiruvarur, Tamil Nadu, 610005, India.
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, India.
Appl Biochem Biotechnol. 2021 Jun;193(6):1780-1799. doi: 10.1007/s12010-021-03498-9. Epub 2021 Jan 25.
Dysbiosis of the gut microbiome has been associated with the development of colorectal cancer (CRC). Gut microbiota is involved in the metabolic transformations of dietary components into oncometabolites and tumor-suppressive metabolites that in turn affect CRC development. In a healthy colon, the major of microbial metabolism is saccharolytic fermentation pathways. The alpha-bug hypothesis suggested that oncogenic bacteria such as enterotoxigenic Bacteroides fragilis (ETBF) induce the development of CRC through direct interactions with colonic epithelial cells and alterations of microbiota composition at the colorectal site. Escherichia coli, E. faecalis, F. nucleatum, and Streptococcus gallolyticus showed higher abundance whereas Bifidobacterium, Clostridium, Faecalibacterium, and Roseburia showed reduced abundance in CRC patients. The alterations of gut microbiota may be used as potential therapeutic approaches to prevent or treat CRC. Probiotics such as Lactobacillus and Bifidobacterium inhibit the growth of CRC through inhibiting inflammation and angiogenesis and enhancing the function of the intestinal barrier through the secretion of short-chain fatty acids (SCFAs). Crosstalk between lifestyle, host genetics, and gut microbiota is well documented in the prevention and treatment of CRC. Future studies are required to understand the interaction between gut microbiota and host to the influence and prevention of CRC. However, a better understanding of bacterial dysbiosis in the heterogeneity of CRC tumors should also be considered. Metatranscriptomic and metaproteomic studies are considered a powerful omic tool to understand the anti-cancer properties of certain bacterial strains. The clinical benefits of probiotics in the CRC context remain to be determined. Metagenomic approaches along with metabolomics and immunology will open a new avenue for the treatment of CRC shortly. Dietary interventions may be suitable to modulate the growth of beneficial microbiota in the gut.
肠道微生物组的失调与结直肠癌(CRC)的发展有关。肠道微生物参与膳食成分代谢转化为致癌代谢物和肿瘤抑制代谢物,进而影响 CRC 的发展。在健康的结肠中,微生物代谢的主要途径是糖发酵途径。α-细菌假说表明,致癌细菌,如肠毒素脆弱拟杆菌(ETBF),通过与结肠上皮细胞的直接相互作用以及结直肠部位微生物组成的改变,诱导 CRC 的发展。大肠杆菌、粪肠球菌、产单核细胞李斯特菌和酿脓链球菌的丰度较高,而 CRC 患者中双歧杆菌、梭状芽孢杆菌、真杆菌和罗氏菌的丰度降低。肠道微生物组的改变可作为预防或治疗 CRC 的潜在治疗方法。益生菌,如乳杆菌和双歧杆菌,通过抑制炎症和血管生成以及通过分泌短链脂肪酸(SCFAs)增强肠道屏障功能来抑制 CRC 的生长。生活方式、宿主遗传和肠道微生物组之间的相互作用在 CRC 的预防和治疗中得到了很好的证明。需要进一步的研究来了解肠道微生物组与宿主之间的相互作用,以影响和预防 CRC。然而,也应该考虑到 CRC 肿瘤异质性中细菌失调的相互作用。宏转录组学和宏蛋白质组学研究被认为是理解某些细菌菌株抗癌特性的有力组学工具。益生菌在 CRC 背景下的临床获益仍有待确定。宏基因组学方法以及代谢组学和免疫学将为 CRC 的治疗开辟新途径。饮食干预可能适合调节肠道中有益菌群的生长。